Dr. Brigid Maura Freyne, MD

Dr. Freyne practices at Brigid Freyne MD in Murrieta, California.

Dr. Freyne's NPI, 1689640856, was assigned on February 27, 2006. Dr. Freyne graduated from Saint Louis University School Of Medicine in 1996. Dr. Freyne's California license number on file is A64382.

Dr. Freyne's primary practice is Brigid Freyne MD, at 39755 Murrieta Hot Springs Rd, Murrieta, CA 92563-9101. The practice phone is (951) 696-4600.

Dr. Freyne's primary practice is Brigid Freyne MD in Murrieta, California. Dr. Freyne is also affiliated with Loma Linda University Medical Center - Murrieta.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Freyne practices, 2 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Freyne's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Freyne is board certified in certified principal investigator by the Academy of Clinical Research Professionals. Dmand AI has Dr. Freyne's licenses on file in 2 states: California and Nevada.

Dmand AI lists arteritis, arthritis, gout, joint pain, lupus, muscle pain, fibromyalgia, and limb pain, osteoporosis and rheumatoid arthritis among the conditions Dr. Freyne treats.

CMS data shows 97,321 Medicare services from Dr. Freyne across 45 procedure codes in 2024, for 694 Medicare patients. Medicare paid $1,692,783 for them. Every service was in an office.

CMS counts 694 Medicare patients who saw Dr. Freyne in 2024. The largest group is 65 to 74, with 312 patients. 75% of them have arthritis, and 75% have high blood pressure. 16% are also on Medicaid. Their average risk score is 1.25, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Freyne's median patient age at 68, with 77% women.

In 2024, Dr. Freyne wrote 8,386 Medicare Part D claims for 770 patients. 86% of them were for generic drugs. CMS names the drug for 7,766 of them, across 117 drugs with 11 or more claims each, at $3,318,356 in total drug cost. In 2023, CMS named 7,621 claims across 119 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Freyne for performance year 2024, reported individually. Dr. Freyne accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Freyne in 2022. Dr. Freyne's most frequent co-authors are Abdul Ali Abdellatif, MD, John A. Albert, MD and Herbert Stuart Block Baraf, MD.

Dmand AI links Dr. Freyne to 3 clinical trials. Conditions studied include Arthritis, Rheumatoid, Bursitis and Dupuytren Contracture. Endo Pharmaceuticals sponsors the most, 2.

CMS Open Payments shows 2,946 general payments to Dr. Freyne from 94 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 41% of the total. Horizon Pharma plc paid the most, $127,410. It also lists 19 research payments totaling $422,081 from 2016 to 2018.

Dmand AI lists 1 award for Dr. Freyne.

Dr. Freyne graduated from Saint Louis University School Of Medicine in 1996. Dr. Freyne is a member of ACR.

Dr. Freyne is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.